Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. Krka and Krka Group Unaudited Report Q1 2024.pdfKrka and Krka group unaudited report Q1 2024
  2. Press Release.pdfPress release

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 27 / 2024
Date of issue: 2024-05-16
Short name of the issuer
KRKA
Subject
Unaudited Interim Report of the Krka Group and the Krka, d. d., Novo mesto for the first quarter of 2024
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
Based on Article 26 of the Rules of the Ljubljana Stock Exchange d.d. company Krka, d. d., Novo mesto publishes the Unaudited interim Report of the Krka Group and Krka, d. d., Novo mesto for the first quarter of 2024.


The report will be published on the Company's website (www.krka.biz) from 16 May 2024 onwards, for a period of at least 5 years.
Annexes
File Description
Krka and Krka Group Unaudited Report Q1 2024.pdf
Krka and Krka Group Unaudited Report Q1 2024.pdf		 Krka and Krka group unaudited report Q1 2024
Press Release.pdf
Press Release.pdf		 Press release

KRKA, TOVARNA ZDRAVIL D.D.
(fullname of the issuer)
KRKA Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
8501 Nove Mesto
(post code) (city)
Smarjeska 6
(street) (number)
+386 7 331 21 11 +386 7 332 15 37
(phone number) (fax)
(e-mail) (web site)
nie dotyczy
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2024-05-16 Jože Colarič President of the Management Board and CEO
20240524_091142_1453494324_Krka_and_Krka_Group_Unaudited_Report_Q1_2024.pdf

Pobierz
20240524_091142_1453494324_Press_Release.pdf

Pobierz